Anitocabtagene autoleucel (anito-cel), an anti-BCMA CAR T-cell therapy, is evaluated in the iMMagine-1 Phase 2 trial for relapsed/refractory multiple myeloma (RRMM). The study aims to assess safety and efficacy in heavily pretreated patients. Results show a high overall response rate (97%) with deep responses (62% complete response) and favorable safety profiles including manageable cytokine release syndrome and neurotoxicity.

Key Points:

• Research Problem/Question: Evaluate anito-cel efficacy in RRMM.
• Methodology: Phase 2 trial with autologous CAR T-cell therapy.
• Key Findings: 97% overall response rate, 62% complete response rate, and 93.1% achieving MRD negativity.
• Significance/Impact: Demonstrates promising efficacy in advanced RRMM, highlighting CAR T-cell therapy's potential in refractory disease.

Conclusion:
The iMMagine-1 trial updates underscore anito-cel's robust efficacy and manageable safety in RRMM, supporting its potential as a therapeutic option in heavily pretreated patients.

Authors: 
Gurbakhash Kaur,  Ciara L. Freeman,  Binod Dhakal,  Richard T. Maziarz,  Natalie Callander,  Adam S. Sperling,  Carolina D. Schinke,  Andrzej J. Jakubowiak,  Noa Biran,  Douglas W. Sborov,  Cindy Varga,  Larry D. Anderson, Jr.,  Abhinav Deol,  Abraham S. Kanate,  Mehmet H. Kocoglu,  Melhem M. Solh,  Kamalika Banerjee,  Krishna Rana,  Ana Kostic,  Enrique Granados,  Carolyn C. Jackson,  Christopher R. Heery,  Tim Welliver,  Krina K. Patel,  Matthew J. Frigault

EHA Abstract #S201